Navigation Links
Labopharm to host conference call Thursday, February 21, 2008 at 8:30 a.m. (ET)
Date:2/12/2008

- Management to discuss fourth quarter financial results -

LAVAL, QC, Feb. 12 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that it will host a conference call on Thursday, February 21 at 8:30 a.m. (ET) to discuss its fourth quarter 2007 financial results. Labopharm will report its fourth quarter 2007 financial results via news release at approximately 7:00 a.m. the same day.

To access the conference call by telephone, dial 416-644-3418 or 1-800-732-0232. Please connect approximately 15 minutes prior to the beginning of the call to ensure participation. The conference call will be archived for replay until Thursday, February 28, 2008 at midnight. To access the archived conference call, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21260670 followed by the number sign.

A live audio webcast of the conference call will be available at http://www.labopharm.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above web site for 30 days.

About Labopharm Inc.

Labopharm is an emerging leader in optimizing the performance of existing small molecule drugs using its proprietary controlled-release technologies. The Company's lead product, a unique once-daily formulation of tramadol, is being commercially launched in key markets globally. The Company also has a robust pipeline of follow-on products in both pre-clinical and clinical development. Labopharm's vision is to become a fully integrated, international, specialty pharmaceutical company with the capability to internally develop and commercialize its own products. For more information, please visit http://www.labopharm.com.

This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the price of the Company's shares, the uncertainties related to the regulatory process for drug approval and the commercialization of the Company's products, if they are approved. Investors should consult the Company's ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements.


'/>"/>
SOURCE Labopharm Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... ... awarded accreditation with distinction by the Undersea and Hyperbaric Medical Society (UHMS), the ... with advanced care and patient safety. Only a few hospitals and facilities have ...
(Date:12/8/2016)... ... 08, 2016 , ... Mirixa Corporation , a leading ... pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to senior ... of sales. , Litsinger joined Mirixa in 2008 after serving as a ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to redefine ... are both engaging and easy to use. Coming off the heels of a ... today its plans to roll out new AI-powered self-service enhancements to help organizations ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... California Senate ... medical payments per workers’ compensation claim in 2013 and 2014, according to CompScope™ ... Research Institute (WCRI) . , According to the study, medical payments per claim in ...
(Date:12/8/2016)... OH (PRWEB) , ... December 08, 2016 , ... ... insurance and financial planning services from offices headquartered in Hamilton County, is embarking ... rescue LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... External Defibrillators, Implantable Cardioverter ... ICD, Cardiac Resynchronization Therapy Defibrillators (CRT-D), Manual External ... The global defibrillators market is ... from 2016-2020 and CAGR of 5.1% from 2020-2026. ... CAGR of 5.2% from 2016 to 2026. The ...
(Date:12/9/2016)... Research and Markets has announced the addition of the "High Throughput ... ... the market by the following Technology Types: Label-Free Technology, Cell-Based Assay, and ... Canada , Japan , Europe ... and Rest of World. Annual estimates and forecasts are ...
(Date:12/9/2016)... Research and Markets has announced the ... 2021" report to their offering. ... Market growth can be ... the pharmaceutical and biotechnology industry and technological advancements like automation ... markets and growing research activities in toxicology and stem cells ...
Breaking Medicine Technology: